Reports

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

MEDICAL FRONTIERS - International Conference on Alzheimer’s Disease (ICAD 2009)

Advances in the Treatment of Alzheimer’s Disease

Vienna, Austria / July 11-16, 2009

Vienna - Current predictions estimate that by 2050, one in 85 people worldwide will have Alzheimer’s disease (AD). With this rising prevalence over the coming decades, physicians must recognize the value of earlier diagnosis and...

PRIORITY PRESS - International Conference on Alzheimer’s Disease

Progress on the Therapeutic Front

Vienna, Austria / July 11-16, 2009

Vienna - The cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine improve cognition, functional abilities and behaviour when introduced early on in patients with Alzheimer’s disease (AD). Importantly,...

MEDICAL FRONTIERS - 61st Annual Meeting of the American Academy of Neurology

Safety at the Forefront of Emerging Therapies in Multiple Sclerosis

Seattle, Washington / April 25-May 2, 2009

Seattle - Drug development for control of multiple sclerosis appears to be accelerating. An increasing number of mechanisms for treatment of autoimmune processes are being derived from detailed long-term studies with established agents as...

Multiple Sclerosis, Vol. 15, No. 1, 50-58 (2009)

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis

A Gajofatto Multiple Sclerosis Center, Department of Neurology, University of California, San...

Background Options for non-responders to relapsing–remitting multiple sclerosis (RRMS) first-line disease-modifying therapies (DMT) are limited. We explored whether switching first-line DMT is effective. Methods Patients with RRMS who...

MEDICAL OPTIONS in Neuro-Oncology

Currrent Trends and Future Perspectives in Glioblastoma Multiforme - Reviews from published literature

Recurrence Patterns in Gliomas Dr. Normand Laperrière, University of Toronto Management of Recurrent Glioblastoma Multiforme Dr. Rolando Del Maestro, McGill University Rechallenge with Temozolomide: Dosing Strategies Dr. James R. Perry,...

MEDICAL OPTIONS in Neuropathic Pain

Defining Neuropathic Pain and Optimizing Treatment Approaches - Reviews from published literature

December 2008

Mechanisms of Action Guide Rational Choice of Therapy in Neuropathic Pain Dr. May Ong-Lam, University of British Columbia Optimal Therapeutic Choices in Neuropathic Pain Must Be Individualized Mr. Robert Thiffault, Centre hospitalier...

PRIORITY PRESS - 2nd World Congress on Controversies in Neurology

Early Treatment of Multiple Sclerosis: A BENEFIT Review

Athens, Greece / October 23-26, 2008

Rationale for Early MS Treatment Multiple sclerosis (MS) is the major neurologic disease of young adults, the group most likely to benefit from the prevention of early onset of progressive disease and long-term disability. “One very...

PRIORITY PRESS - Fibromyalgia and Sleep Disorders Scientific Conference

Sleep Disorders: An Integral Component of the Fibromyalgia Syndrome

Portland, Oregon / October 2-4, 2008

Fibromyalgia occurs in 2% to 4% of the general population. Dr. I. Jon Russell, Associate Professor of Medicine, Division of Clinical Immunology, University of Texas Health Science Center, San Antonio, noted that the prevalence increases...

World Congress on Treatment and Research in Multiple Sclerosis (ACTRIMS - ECTRIMS - LACTRIMS)

Update on Treatment of Multiple Sclerosis and Clinically Isolated Syndrome

Montreal, Quebec / September 17-20, 2008

Montreal - Disease-modifying therapy with glatiramer acetate (GA) has favorably changed the course of multiple sclerosis (MS) when used early in the disease process. When initiated at the first neurological attack, GA protects cerebral...

PAGE 4 OF 9   1 2 3 4 5 6 7 8 9